Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BTAI NASDAQ:NERV NASDAQ:SNPX NASDAQ:SPRB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBTAIBioXcel Therapeutics$1.95+2.6%$1.67$1.17▼$21.92$11.51M0.041.23 million shs288,557 shsNERVMinerva Neurosciences$2.11+16.1%$1.69$1.15▼$3.38$12.68M-0.3422,569 shs128,413 shsSNPXSynaptogenix$9.70-6.6%$4.49$1.84▼$7.85$13.48M1.08246,558 shs420,936 shsSPRBSpruce Biosciences$0.10+4.2%$0.07$0.06▼$0.61$4.08M2.4694,981 shs33,969 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBTAIBioXcel Therapeutics+2.63%-2.50%+15.38%+12.07%-90.90%NERVMinerva Neurosciences+16.07%+22.95%+18.26%+31.56%-37.16%SNPXSynaptogenix-6.60%+18.23%+127.05%+358.39%+118.36%SPRBSpruce Biosciences+4.24%+38.51%+35.90%-15.16%-82.93%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBTAIBioXcel Therapeutics4.2086 of 5 stars3.32.00.04.53.71.70.6NERVMinerva Neurosciences4.2071 of 5 stars3.05.00.04.62.00.01.3SNPXSynaptogenix0.3115 of 5 stars0.02.00.00.03.80.00.0SPRBSpruce Biosciences2.0419 of 5 stars3.03.00.00.00.61.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBTAIBioXcel Therapeutics 2.67Moderate Buy$42.602,084.62% UpsideNERVMinerva Neurosciences 2.00Hold$5.00137.53% UpsideSNPXSynaptogenix 0.00N/AN/AN/ASPRBSpruce Biosciences 2.00Hold$1.751,637.84% UpsideCurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBTAIBioXcel Therapeutics$2.27M5.21N/AN/A($30.01) per share-0.06NERVMinerva NeurosciencesN/AN/A$0.24 per share8.68($3.67) per shareN/ASNPXSynaptogenixN/AN/AN/AN/A$4.33 per shareN/ASPRBSpruce Biosciences$4.91M0.87N/AN/A$1.88 per share0.05Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBTAIBioXcel Therapeutics-$59.60M-$13.55N/AN/AN/A-2,163.18%N/A-83.80%8/5/2025 (Estimated)NERVMinerva Neurosciences$1.44M$0.822.57N/AN/AN/A-20.68%15.73%8/5/2025 (Estimated)SNPXSynaptogenix-$12.77M-$10.08N/A∞N/AN/A-115.28%-58.31%N/ASPRBSpruce Biosciences-$47.92M-$1.32N/AN/AN/A-555.23%-62.10%-47.49%8/11/2025 (Estimated)Latest SPRB, SNPX, BTAI, and NERV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/11/2025Q2 2025SPRBSpruce Biosciences-$0.25N/AN/AN/A$0.67 millionN/A8/5/2025Q2 2025BTAIBioXcel Therapeutics-$2.30N/AN/AN/A$0.21 millionN/A8/5/2025Q2 2025NERVMinerva Neurosciences-$0.95N/AN/AN/AN/AN/A5/15/2025Q1 2025SNPXSynaptogenixN/A$0.04N/A$0.04N/AN/A5/13/2025Q1 2025NERVMinerva Neurosciences-$1.07-$0.50+$0.57-$0.50N/AN/A5/12/2025Q1 2025BTAIBioXcel Therapeutics-$2.72-$1.50+$1.22-$1.50$0.35 million$0.17 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBTAIBioXcel TherapeuticsN/AN/AN/AN/AN/ANERVMinerva NeurosciencesN/AN/AN/AN/AN/ASNPXSynaptogenixN/AN/AN/AN/AN/ASPRBSpruce BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBTAIBioXcel TherapeuticsN/A1.481.45NERVMinerva NeurosciencesN/A9.219.21SNPXSynaptogenixN/A72.5972.59SPRBSpruce Biosciences0.015.365.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBTAIBioXcel Therapeutics30.68%NERVMinerva Neurosciences34.56%SNPXSynaptogenix10.34%SPRBSpruce Biosciences91.71%Insider OwnershipCompanyInsider OwnershipBTAIBioXcel Therapeutics21.20%NERVMinerva Neurosciences8.60%SNPXSynaptogenix2.73%SPRBSpruce Biosciences6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBTAIBioXcel Therapeutics906.06 million4.77 millionOptionableNERVMinerva Neurosciences9N/AN/ANot OptionableSNPXSynaptogenix41.39 million1.35 millionNot OptionableSPRBSpruce Biosciences2042.23 million37.54 millionOptionableSPRB, SNPX, BTAI, and NERV HeadlinesRecent News About These CompaniesSPRB Spruce Biosciences, Inc. - Seeking AlphaJune 24, 2025 | seekingalpha.comSpruce Biosciences gets conditional approval to resume trading on Nasdaq Capital MarketJune 13, 2025 | msn.comSpruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital MarketJune 12, 2025 | finance.yahoo.comSpruce Biosciences’ Compliance Plan Accepted by NasdaqJune 12, 2025 | tipranks.comSpruce Biosciences’ SWOT analysis: stock pivots amid clinical setbacksMay 7, 2025 | investing.comSpruce Biosciences Inc Ordinary SharesMay 6, 2025 | morningstar.comMSpruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate UpdatesMay 6, 2025 | finance.yahoo.comSpruce Axes 55% of Staff, Leaving Shoestring Crew To Focus on New Rare Disease AssetApril 28, 2025 | biospace.comBSpruce halves head count, narrowing focus to get ex-BioMarin drug to FDAApril 28, 2025 | fiercebiotech.comFSpruce Biosciences (SPRB) Receives a Hold from RBC CapitalApril 17, 2025 | markets.businessinsider.comSpruce Biosciences, Inc. (NASDAQ:SPRB) Q1 2023 Earnings Call TranscriptApril 17, 2025 | insidermonkey.comSpruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)April 15, 2025 | standard-journal.comSWith BioMarin deal, Spruce Biosciences hits reset on rare-disease drugApril 15, 2025 | bizjournals.comSpruce Biosciences, Inc. (SPRB) Corporate Update Conference Call (Transcript)April 15, 2025 | seekingalpha.comSpruce Biosciences reports delayed annual filingApril 3, 2025 | investing.comSpruce Biosciences Inc (SPRB) Stock: Understanding Its Underlying ValueFebruary 5, 2025 | bovnews.comBHold Rating for Spruce Biosciences Amid Clinical Setbacks and Strategic UncertaintiesDecember 16, 2024 | markets.businessinsider.comSpruce Biosciences (SPRB) Upgraded to Buy: Here's WhyDecember 13, 2024 | zacks.comJMP Securities Downgrades Spruce Biosciences (SPRB)December 12, 2024 | msn.comSpruce saws off only drug after 2nd hyperplasia fail, leaving biotech's direction in doubtDecember 11, 2024 | fiercebiotech.comFNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSPRB, SNPX, BTAI, and NERV Company DescriptionsBioXcel Therapeutics NASDAQ:BTAI$1.95 +0.05 (+2.63%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$1.94 -0.01 (-0.77%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.Minerva Neurosciences NASDAQ:NERV$2.10 +0.29 (+16.07%) Closing price 07/16/2025 04:00 PM EasternExtended Trading$2.08 -0.03 (-1.43%) As of 04:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.Synaptogenix NASDAQ:SNPX$9.70 -0.69 (-6.60%) As of 07/15/2025Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. It also evaluates therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. The company was incorporated in 2012 and is headquartered in New York, New York.Spruce Biosciences NASDAQ:SPRB$0.10 +0.00 (+4.24%) As of 07/16/2025 03:32 PM EasternSpruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Just Triggered a Signal Traders Can’t Ignore JNJ’s Stock Price Is Back in Rally Mode—The Time to Buy Is Now This ASML Dip Could Be Gone Before You Know It—Don’t Miss Out Rocket Lab Gets New Street-High Price Target from Citi Super Micro Stock May Benefit as Cooling Demand Takes Off Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings Salesforce Stock Set for 30% Upside to Reach New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
